NCT03526835: A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients will not be eligible for the expansion cohort
Exclusions: Patients with central nervous system metastases that are untreated, symptomatic, and/or require therapy; Patients with known leptomeningeal involvement

Comments are closed.

Up ↑